Viridian Therapeutics (VRDN) Earnings Analysis
Viridian Therapeutics (VRDN) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it missed with EPS -1.08 USD vs -0.9 USD est (-20%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -5.51.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does VRDN next report earnings?
No confirmed upcoming earnings date is currently scheduled for VRDN. This page updates as the calendar is published.
VRDN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | -1.08 USD | -0.9 USD | -20% | Miss |
| 2025-02-27 | -0.81 USD | -1.05 USD | +22.9% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
VRDN valuation and analyst view
| Trailing P/E | -5.51 |
|---|---|
| Trailing EPS | -3.52788 USD |
| Price / book | 3.08 |
| Dividend yield | 0.00% |
| Market cap | 1.70B |
| Analyst consensus | Buy (14 buy / 2 hold / 0 sell) |
| Avg price target | 35.63 USD |
Related research pages
Frequently asked questions
When is Viridian Therapeutics (VRDN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for VRDN. This page updates as the calendar is published.
Did VRDN beat earnings last quarter?
In its 2026-02-26 report, VRDN posted EPS of -1.08 USD versus a -0.9 USD estimate — a miss of 20%.
What is VRDN's earnings track record?
Over the last 2 reported quarters with consensus data, VRDN beat estimates 1 times (50%).
What is VRDN's current P/E ratio and EPS?
VRDN trades at a trailing P/E of -5.51 on trailing EPS of -3.527875494670828 USD.
What do analysts rate VRDN?
Analyst consensus is "Buy" across 16 ratings (0 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 35.63 USD.